Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
cQuest
Bothell, Washington, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
C-Quest was a biotechnology company focused on the development of RNA interference (RNAi) therapeutics and technologies. The company specialized in creating novel methods for gene silencing, particularly through the design and delivery of small interfering RNA (siRNA) molecules. C-Quest's proprietary technology platform was designed to enhance the stability and efficacy of RNAi-based drugs, addressing key challenges in the field of nucleic acid medicine. In 2008, the company was acquired by MDRNA (now known as Marina Biotech), which integrated C-Quest's intellectual property and expertise into its broader portfolio of RNA-based therapeutic programs.
- Modalities
- RNA therapySmall interfering RNA
- Industry
- Biotech
02
Partnerships
MDRNA
Beyond the preview
Go deeper on cQuest.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cQuest.